Amicus Leader, BIO Board Member John Crowley Named Trade Group’s New CEO
BIO’s new president and CEO is a familiar face. John Crowley, a longtime BIO board member, was named the life sciences industry trade group’s new leader, starting in March.
Amicus Therapeutics Rare Disease Combo Therapy Wins Long-Awaited FDA Nod
Sanofi dominates the market for therapies that treat Pompe disease, a rare enzyme deficiency. The FDA has approved an Amicus Therapeutics combination treatment for patients inadequately served by the Sanofi products.
presented by
The Top-Rated Orthopedic Surgery Centers in the Houston Area and Beyond
Discover Houston's best orthopedic surgery centers and what features — from personalized treatment plans to rehabilitation services — make these top providers stand out in their industry.
Amicus rejiggers gene therapy plans as SPAC merger folds in unfriendly market
The SPAC merger that Amicus Therapeutics planned for its gene therapy assets has been called off due to market conditions. The rare disease company is instead keeping those assets but streamlining its portfolio in order to save $400 million—the amount that the gene therapy spinout was in line to receive from the merger deal.
Amicus deal puts it on path to profitability, infuses its gene therapies with $400M
Amicus Therapeutics is spinning its gene therapy pipeline into a separate entity that will go public via a SPAC merger. Executives say the transaction puts Amicus on a path to profitability while simultaneously securing the cash needed to develop the gene therapy assets.
Amicus’s path to unseat Sanofi in rare disease gets steeper after Phase 3 miss
Amicus Therapeutics CEO John Crowley said the totality of data support the Pompe disease therapy’s submission to the FDA. That rolling application is on track for completion in the second quarter.
Fresh off first FDA approval, Amicus spends $100M to acquire 10 gene therapies
The company acquired 10 AAV-based gene therapies in development for lysosomal storage disorders, including two already in early clinical trials.
presented by
5 Major Trends Emerging in Healthcare Benefits in 2025
Employees who enjoy their benefits are more inclined to stay with their company. A 2025 Marsh McLennan Agency report said 73% of employees would remain if plan options were better.
Morning Read: Renowned neurologist and author Oliver Sacks dies, Amicus acquires Scioderm in a $229M deal
Renowned neurologist and author Oliver Sacks has died of cancer at the age of 82, Amicus Therapeutics has acquired a drug to treat a rare skin disorder through its purchase of Scioderm in a $229 million deal.
Amicus Therapeutics names new CFO
Amicus Therapeutics (NASDAQ:FOLD) has hired a biopharmaceutical industry veteran as chief financial officer of its business to develop treatments for lysosomal storage diseases and neurodegenerative diseases. William D. Baird III previously worked at PTC Therapeutics where he served for 10 years, seven as CFO, according to a company statement. Amicus’ lead drug undergoing phase 3 […]